Acura Pharmaceuticals has appointed Garth Boehm as its new vice president of modified release dosage form development.
Subscribe to our email newsletter
Dr Boehm is currently employed as vice president of product development at Actavis Pharmaceuticals and is expected to commence employment with Acura in May 2009.
Andy Reddick, president and CEO of Acura, said: “We are delighted that Dr Boehm will be joining our talented research, development, and senior management teams. We look forward to working with Dr Boehm as we remain intensely focused on developing a broad array of proprietary products with unique abuse deterrent features and benefits.”
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.